Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27997027 | 0.86 | ERN1 (0.48) | ERN1PTGDR2CYP2A6SRCLMNA | |
| SCHEMBL3654095 | 0.83 | ERN1 (0.48) | ERN1PTGDR2CYP2A6LMNAPTPN1 | |
| SCHEMBL29793157 | 0.83 | ERN1 (0.48) | ERN1PTGDR2CYP2A6LMNAPTPN1 | |
| SCHEMBL16956364 | 0.82 | ERN1 (0.38) | ERN1PTGDR2LMNAHPGDTSHR | |
| SCHEMBL26655793 | 0.82 | ERN1 (0.57) | ERN1PTGDR2CYP2A6SRCPTPN1 | |
| SCHEMBL16962173 | 0.82 | ERN1 (0.42) | ERN1PTGDR2LMNAHPGDTSHR | |
| SCHEMBL38665606 | 0.80 | ERN1 (0.50) | ERN1PTGDR2CYP2A6SRCPTPN1 | |
| SCHEMBL7872295 | 0.79 | ERN1 (0.48) | ERN1PTGDR2CYP2A6SRCLMNA | |
| SCHEMBL10497451 | 0.77 | SRC (0.42) | CYP2A6SRCLMNAHPGDALDH1A1 | |
| SCHEMBL13180289 | 0.77 | SRC (0.65) | ERN1CYP2A6SRCLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12084472-B2 | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists | ARDELYX, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20220411377-A1 | SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NORTHWESTERN UNIVERSITY | 2022-12-29 | — | — | US | disclosed |
| US-20220306672-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| EP-3390382-B1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3390382-B1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2021-12-01 | — | — | EP | disclosed |
| CN-108699028-B | Substituted 4-phenylpyridines as non-systemic TGR5 agonists | 阿德利克斯公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-2021081528-A1 | SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2021-04-29 | — | — | WO | disclosed |
| US-10968246-B2 | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists | ARDELYX, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2008057469-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | WYETH (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057497-A2 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057468-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057497-A2 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080058521-A1 | Processes for the preparation of compounds | WYETH (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058521-A1 | Processes for the preparation of compounds | WYETH (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058521-A1 | Processes for the preparation of compounds | WYETH (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008028118-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SMITHKLINE BEECHAM CORPORAITON (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007089669-A2 | PROCESSES FOR THE PREPARATION OF COMPOUNDS WHICH MODULATE CELL PROLIFERATION | WYETH (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089669-A2 | PROCESSES FOR THE PREPARATION OF COMPOUNDS WHICH MODULATE CELL PROLIFERATION | WYETH (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411377-A1 | SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NOS3, NOS1, NOS2 | ERN1 2796/4885PTGDR2 793/4885CYP2A6 1219/4885 |
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, GLP1R | ERN1 3233/4885PTGDR2 160/4885CYP2A6 2024/4885 |
| US-20080058521-A1 | Processes for the preparation of compounds | MKI67, MCL1, DCX | ERN1 2740/4885PTGDR2 1054/4885CYP2A6 1491/4885 |
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, FFAR3 | ERN1 1789/4885PTGDR2 733/4885CYP2A6 535/4885 |
| US-10968246-B2 | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists | GPR119, GIPR, GLP1R | ERN1 3233/4885PTGDR2 160/4885CYP2A6 2024/4885 |
| US-20220306672-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, GLP1R | ERN1 3233/4885PTGDR2 160/4885CYP2A6 2024/4885 |
| US-12084472-B2 | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists | GPR119, GIPR, GLP1R | ERN1 3233/4885PTGDR2 160/4885CYP2A6 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.